Older Adults Respond Well to Immunotherapy Despite Age-Related Immune System Differences

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins Convergence Institute. The study was supported in part by the National Institutes of Health, including the National Cancer Institute's Specialized Programs of Research Excellence.